Activating Mutations in PTPN11 and KRAS in Canine Histiocytic Sarcomas

Genes (Basel). 2019 Jul 4;10(7):505. doi: 10.3390/genes10070505.


While the genetic contributions to the predisposition of Bernese mountain dogs (BMDs) to histiocytic sarcoma (HS) remains unclear, some insights into key genetic drivers have been gained. Our group recently reported a mutation in the PTPN11 gene (E76K). We have now identified a second missense mutation in PTPN11 (G503V), and a mutation in KRAS (Q61H) present in HS cell lines. These mutations are associated with malignancies in humans, and known to be gain-of-function mutations that result in activation of the mitogen-activated protein kinase (MAPK) pathway. The goal of the present study was to evaluate the prevalence of these mutations in a large sample of HS cases from BMDs and golden retrievers, and in lymphoma cases, from a cohort of BMDs. Mutations in PTPN11 were present in HS in 41/96 (43%) BMDs, and in 3/13 (23%) golden retrievers. PTPN11 mutations E76K and G503V did not coexist in the same neoplasm. The KRAS mutation was much less frequent, with a prevalence of 3.1% (3/96). We did not identify either PTPN11 nor KRAS mutations in any of the lymphoma samples. These results point out the potential relevance of PTPN11 and KRAS mutations as activators of the oncogenic MAPK pathway for canine HS, particularly in BMDs.

Keywords: Bernese mountain dog; KRAS; PTPN11; histiocytic sarcoma; somatic mutation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Dog Diseases / genetics*
  • Dogs / genetics*
  • Female
  • Gain of Function Mutation
  • Histiocytic Sarcoma / genetics*
  • MAP Kinase Signaling System
  • Male
  • Protein Tyrosine Phosphatase, Non-Receptor Type 11 / genetics*
  • Proto-Oncogene Proteins p21(ras) / genetics*


  • Protein Tyrosine Phosphatase, Non-Receptor Type 11
  • Proto-Oncogene Proteins p21(ras)